Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$62.48

-0.54 (-0.86%)

, HALO

Halozyme

$13.18

0.12 (0.92%)

07:04
09/14/17
09/14
07:04
09/14/17
07:04

Halozyme to receive $150M from Bristol-Myers for Enhanze technology partnership

Bristol-Myers (BMY) and Halozyme (HALO) announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme's Enhanze drug-delivery technology. The Halozyme Enhanze technology is based on a proprietary recombinant human hyaluronidase enzyme to aid in the dispersion and absorption of other injected therapeutic drugs. Halozyme will receive an initial $105M for access to the Enhanze technology. Bristol-Myers Squibb has an option to select additional targets within five years from the effective date. The collaboration may extend to a maximum of 11 targets. Halozyme has the potential to earn milestone payments of up to $160M for each of the nominated collaboration targets and additional milestone payments for combination products. In addition, Bristol-Myers Squibb will pay Halozyme royalties on sales of products using the Enhanze technology developed under the collaboration. For Bristol-Myers, the transaction is expected to be dilutive to non-GAAP EPS in 2017 and 2018 by approximately 1c, and by approximately 5c in 2019.

BMY

Bristol-Myers

$62.48

-0.54 (-0.86%)

HALO

Halozyme

$13.18

0.12 (0.92%)

  • 24

    Sep

  • 25

    Sep

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

BMY Bristol-Myers
$62.48

-0.54 (-0.86%)

08/16/17
LEER
08/16/17
NO CHANGE
Target $34
LEER
Outperform
Leerink sees competitor setback in RCC opportunity for Exelixis
Leerink analyst Michael Schmidt notes that Bristol-Myers (BMY) reported top-line results from the Phase III CheckMate-214 trial investigating Opdivo in combination with Yervoy versus Sutent in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma, or RCC. While directionally positive, the trial missed the co-primary endpoint of improving progression-free survival with statistical significance, he notes, adding that this raises the regulatory bar for Bristol-Myers' IO combination at least until positive overall survival data are available likely in mid-2019, which he thinks will be positively received by Exelixis (EXEL) investors. Following the news, Schmidt believes Exelixis continues to look well positioned in RCC, He reiterates an Outperform rating and $34 price target on the latter's shares.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Overweight
Incyte melanoma data exceeded expectations, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the data on the use of an epacadostat/PD- 1 combo in melanoma treatment presented in an ESMO abstract exceeds expectations and "leaves little doubt" about the combination's efficacy. The analyst, who added that Incyte's (INCY) PFS data exceeds that of a combination of Bristol-Myers' (BMY) Opdivo with Yervoy, keeps an Overweight rating on Incyte and said the data bodes well for the company's Phase 3 program.
09/12/17
HDLY
09/12/17
DOWNGRADE
Target $65
HDLY
Neutral
Bristol-Myers downgraded to Neutral from Long-Term Buy at Hilliard Lyons
Hilliard Lyons analyst Kurt Kemper downgraded Bristol-Myers to Neutral due to share appreciation as shares have approached his previous $65 price target.
09/12/17
09/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Neutral from Long-Term Buy at Hilliard Lyons with analyst Kurt Kemper citing share appreciation as shares have approached his previous $65 price target. 2. Bunge (BG) downgraded to Hold from Buy at Vertical Group citing the acquisition of 70% interest in IOI Loders Croklaan. 3. Advance Auto Parts (AAP) downgraded to Sell from Neutral at Citi with analyst Kate McShane saying the company's turnaround seems to be taking longer given the number of issues to fix, and its cost savings are unlikely to impact earnings given its needed investments. 4. Precision Drilling (PDS) downgraded to Neutral from Overweight at JPMorgan. 5. Nucor (NUE) and Steel Dynamics (STLD) were downgraded to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HALO Halozyme
$13.18

0.12 (0.92%)

01/05/17
PIPR
01/05/17
NO CHANGE
Target $20
PIPR
Overweight
Halozyme price target raised to $20 after pancreas cancer data at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target on Halozyme to $20 from $18, saying the company's "encouraging" Phase 2 data for its pancreas cancer combination treatment reduce the risk to the ongoing Phase 3 program for the combo. Duncan keeps an Overweight rating on Halozyme.
01/06/17
SBSH
01/06/17
DOWNGRADE
Target $14
SBSH
Neutral
Halozyme downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Halozyme Therapeutics to Neutral saying the "mixed" Phase 2 pancreatic cancer data for PEGPH20 suggested the market opportunity is smaller than previously thought. The analyst believes the shares are now fairly valued. He keeps a $14 price target for the name.
03/30/17
DBAB
03/30/17
NO CHANGE
Target $17
DBAB
Buy
Halozyme price target raised to $17 from $15 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme to $17 saying the positive, "unanimous and uncontroversial" FDA Advisory Committee meeting for Rituxan-SC highlights the "strong potential" for the broader Enhanze platform. The analyst reiterates a Buy rating on the shares.
04/17/17
BMOC
04/17/17
INITIATION
Target $14
BMOC
Market Perform
Halozyme initiated with a Market Perform at BMO Capital
BMO Capital initiated Halozyme with a Market Perform and a $714 price target.

TODAY'S FREE FLY STORIES

NBLX

Noble Midstream

$55.58

-0.02 (-0.04%)

16:35
01/18/18
01/18
16:35
01/18/18
16:35
Hot Stocks
Salient reports 6.23% passive stake in Noble Midstream »

This stake does not allow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 20

    Feb

HHS

Harte-Hanks

16:35
01/18/18
01/18
16:35
01/18/18
16:35
Hot Stocks
Harte-Hanks COO/CTO Shirish Lal leaving the company »

Harte Hanks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWGH

GWG Holdings

$8.10

-0.2 (-2.41%)

16:35
01/18/18
01/18
16:35
01/18/18
16:35
Hot Stocks
Breaking Hot Stocks news story on GWG Holdings »

GWG Holdings trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPB

Spectrum Brands

$121.30

-3.86 (-3.08%)

16:32
01/18/18
01/18
16:32
01/18/18
16:32
Hot Stocks
Spectrum Brands postpones 2018 annual shareholder meeting »

Spectrum Brands Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 30

    Jan

  • 08

    Feb

NTIP

Network-1 Technologies

$2.50

0.05 (2.04%)

, JNPR

Juniper

$27.66

-1.01 (-3.52%)

16:32
01/18/18
01/18
16:32
01/18/18
16:32
Hot Stocks
Network-1 Technologies announces revised patent settlement with Juniper »

Network-1 Technologies…

NTIP

Network-1 Technologies

$2.50

0.05 (2.04%)

JNPR

Juniper

$27.66

-1.01 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ENFC

Entegra Financial

$28.90

-0.7 (-2.36%)

16:31
01/18/18
01/18
16:31
01/18/18
16:31
Earnings
Entegra Financial reports Q4 core EPS 54c, consensus 38c »

Reports Q4 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

WYNN

Wynn Resorts

$175.48

1.89 (1.09%)

16:30
01/18/18
01/18
16:30
01/18/18
16:30
Initiation
Wynn Resorts initiated  »

Wynn Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/18/18
01/18
16:30
01/18/18
16:30
Options
Preliminary option volume of 20.9M today »

Preliminary option volume…

NTES

NetEase

$322.19

-2.21 (-0.68%)

16:29
01/18/18
01/18
16:29
01/18/18
16:29
Recommendations
NetEase analyst commentary  »

NetEase price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

MS

Morgan Stanley

$55.84

0.49 (0.89%)

, AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

16:25
01/18/18
01/18
16:25
01/18/18
16:25
General news
On The Fly: Top stock stories for Thursday »

Stocks opened little…

MS

Morgan Stanley

$55.84

0.49 (0.89%)

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

LGF.B

Lionsgate

$32.84

2.46 (8.10%)

CBS

CBS

$60.00

1.1 (1.87%)

VIA

Viacom

$39.70

1.85 (4.89%)

VIAB

Viacom

$33.95

1.99 (6.23%)

BA

Boeing

$340.16

-10.85 (-3.09%)

ERJ

Embraer

$24.50

-0.19 (-0.77%)

GNC

GNC Holdings

$5.26

1.79 (51.59%)

PTC

PTC

$69.95

3.25 (4.87%)

AA

Alcoa

$53.00

-3.99 (-7.00%)

ENDP

Endo

$7.35

-0.34 (-4.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

  • 31

    Jan

  • 01

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 21

    Feb

  • 18

    Mar

SRG

Seritage Growth Properties

$40.37

-0.4 (-0.98%)

16:25
01/18/18
01/18
16:25
01/18/18
16:25
Hot Stocks
Seritage Growth Properties sees FY17 leasing activity 2.6M sqf, up 26% on year »

Seritage Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$66.47

-0.6 (-0.89%)

16:25
01/18/18
01/18
16:25
01/18/18
16:25
Conference/Events
Monster Beverage to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$36.07

-0.47 (-1.29%)

, WYNN

Wynn Resorts

$175.48

1.89 (1.09%)

16:23
01/18/18
01/18
16:23
01/18/18
16:23
Initiation
MGM Resorts, Wynn Resorts, Eldorado Resorts, Penn National initiated  »

MGM Resorts initiated…

MGM

MGM Resorts

$36.07

-0.47 (-1.29%)

WYNN

Wynn Resorts

$175.48

1.89 (1.09%)

ERI

Eldorado Resorts

$31.60

-0.4 (-1.25%)

PENN

Penn National

$32.26

-0.49 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BANF

BancFirst

$55.20

0.95 (1.75%)

16:22
01/18/18
01/18
16:22
01/18/18
16:22
Hot Stocks
BancFirst to raise company minimum wage »

Executive Chairman David…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$23.82

-0.3 (-1.24%)

16:22
01/18/18
01/18
16:22
01/18/18
16:22
Hot Stocks
Meritor realigns segments and leadership positions »

Meritor is realigning its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 13

    Feb

  • 14

    Feb

BANF

BancFirst

$55.20

0.95 (1.75%)

16:21
01/18/18
01/18
16:21
01/18/18
16:21
Earnings
BancFirst reports Q4 EPS 59c, consensus 69c »

Due to the signing of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

16:20
01/18/18
01/18
16:20
01/18/18
16:20
Initiation
athenahealth initiated  »

athenahealth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

VIX

Volatility Index S&P 500 Options

16:20
01/18/18
01/18
16:20
01/18/18
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$99.86

-0.9 (-0.89%)

16:19
01/18/18
01/18
16:19
01/18/18
16:19
Hot Stocks
Breaking Hot Stocks news story on American Express »

American Express down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MRCY

Mercury Systems

$51.26

-0.45 (-0.87%)

16:19
01/18/18
01/18
16:19
01/18/18
16:19
Hot Stocks
Mercury Systems receives $12.5M electronic surveillance subsystem order »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HCLP

Hi-Crush Partners

$12.00

-0.05 (-0.41%)

16:18
01/18/18
01/18
16:18
01/18/18
16:18
Hot Stocks
Hi-Crush Partners increases distribution to 20c per unit for Q4 »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$27.75

-0.4 (-1.42%)

16:17
01/18/18
01/18
16:17
01/18/18
16:17
Earnings
First Financial Bancorp reports Q4 adjusted EPS 45c, consensus 40c »

Claude Davis, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

$NSD

NASDAQ Market Internals

16:17
01/18/18
01/18
16:17
01/18/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRI

Monarch Casino

$45.40

-0.5 (-1.09%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Initiation
Monarch Casino initiated  »

Monarch Casino initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$73.73

0.22 (0.30%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Initiation
Las Vegas Sands initiated  »

Las Vegas Sands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.